September 2023
-
09.25.2023 Updates & Statements Responsibility Pfizer’s Rocky Mount Facility Restarts Production Amid First Phase of Post-Tornado Recovery Efforts -
09.07.2023 Vaccines Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
July 2023
-
07.21.2023 Medicines Pfizer Receives Positive CHMP Opinion for Alopecia Areata Treatment -
07.21.2023 Vaccines Pfizer Receives Positive CHMP Opinion for RSV Vaccine Candidate to Help Protect Infants through Maternal Immunization and Older Adults
June 2023
-
06.30.2023 Vaccines Pfizer and the European Commission Enter into Manufacturing Reservation Agreement for mRNA-based Vaccines to Help Protect Against Future Pandemics -
06.23.2023 Vaccines Pfizer and BioNTech Submit Applications to U.S. FDA for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine -
06.23.2023 Vaccines Pfizer and BioNTech Initiate Application to European Medicines Agency for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine -
06.22.2023 Vaccines Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-valent Pneumococcal Conjugate Vaccine) in Infants and Children -
06.22.2023 Vaccines Pfizer’s ABRYSVO™ Receives Recommendation for Use in Older Adults from Advisory Committee on Immunization Practices -
06.05.2023 Medicines Pfizer Announces DUAVEE® (conjugated estrogens/bazedoxifene), an Estrogen-Based Menopause Hormone Therapy, Now Back in Stock with Improved Packaging
May 2023
-
05.26.2023 Vaccines Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with the European Commission -
05.11.2023 Covid-19 Diseases & Conditions Health Equity Vaccines Global and U.S. Agencies Declare End of COVID-19 Emergency